Considering the turmoil in global markets, gold remains an attractive asset at this point. “We feel that it would be prudent to start with a higher exposure to debt and gold in 2023 and move towards equities in a calibrated manner through superior stock selection. Till there is clarity on the global macroeconomic front, it would be advisable to avoid high beta stocks and stick to cash rich and secular stories to generate superior risk-adjusted returns,” Stoxbox’s Chowdhury said.
Symbiotec Pharmalab sets price band for Rs 1,757 crore IPO, to open on August 24
Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 15 shares,